Navigation Links
Michael J. Fox Foundation awards Mayo Clinic researcher grant to advance Parkinson’s research

JACKSONVILLE, Fla. For his work contributing to a potential new treatment approach for Parkinson's disease, the Michael J. Fox Foundation (MJFF) for Parkinson's Research has awarded a $500,000 grant to a neuroscientist at the Mayo Clinic campus in Florida.

The researcher, Matthew Farrer, Ph.D., studies how a gene, known as LRRK2, functions normally within brain nerve cells (neurons), and also how it can go awry when mutated. Dr. Farrer was part of the original team who discovered the link between LRRK2 and Parkinson's disease in 2004. A year later, he described LRRK2 G2019S, believed now to be the most common genetic risk factor for Parkinson's disease.

For these reasons, MJFF has identified LRRK2 as a high-priority therapeutic target and has invested nearly $17 million to date for a broad and integrated strategy to drive critical LRRK2-related initiatives at every stage of drug development, according to the foundation. As part of those awards, on Feb. 17, MJFF announced grants of $3.5 million to nine research studies.

Dr. Farrer's work in teasing apart the function of LRRK2 in dictating the structure of neurons earned him the two-year grant. The co-principal investigator on the grant is Justus Daechsel, Ph.D., an assistant professor of Molecular Neuroscience at Mayo Clinic.

"At Mayo, our molecular neuroscience research is now focused on the genetic basis of Parkinson's disease, on the specific proteins and the molecular pathways that are affected," Dr. Farrer says. "Our model and drug development program is designed to halt disease progression, not just to treat the symptoms."

Dr. Farrer and his team have genetically altered mice so that they do not have the LRRK2 gene. When brain cells from these animals are grown in laboratory culture, the researchers have found that neurons without LRKK2 branch out more than do neurons with LRRK2, which shows that the gene normally helps regulate neuronal architecture.

They are using the mice to further understand the function of the protein produced by the LRKK2 gene. "It is a large protein, with many parts. So we are going to replace pieces of the protein, with and without the mutations that predispose people to develop Parkinson's disease, back into cells derived from these animals to see what roles different regions of the protein play," he says. They will also delete other proteins known to interact with the LRRK2 protein to see their effect.

"Answers to these questions are critical for future drug development for patients with Parkinson's disease, and we are pleased the support of the Michael J. Fox Foundation can help us reach our common goal," Dr. Farrer says.


Contact: Kevin Punsky
Mayo Clinic

Related medicine news :

1. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
2. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
3. Would You Like to Own a Thriller Album Autographed by Michael Jackson Himself?
4. Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division
5. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
6. Aleres Dr. Michael Taitel Presents Compelling Evidence at IBI/NBCH Health & Productivity Forum that Wellness Programs Positively Impact Health & Productivity
7. Michael Jackson Propofol Expert, Barry Friedberg MD, Spoke at Pan Pacific Surgery Meeting
8. TV Wellness Expert Jillian Michaels Teams With Harley-Davidson to Help Women Channel Their Inner Drive and Live More Fulfilling Lives
9. Michael J. Fox Foundation Awards $2 Million for Clinical Research on Postural Instability and Gait Disturbances in Parkinsons Disease
10. Michael J. Fox Foundation Awards $1 Million for Critical Step Toward Development of Dyskinesia Treatments
11. Rush Limbaugh & Michael Steele Join Tea Party Support & Social Security Institute-Demand GOP Senate Stop ObamaCare by Any Means Possible
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Commitment to Cure last night at the Mandarin Oriental in New York City. ...
(Date:10/13/2015)... ... October 13, 2015 , ... The documentary Pink & Blue: Colors ... Beverly Hills October 2 - 8, coinciding with National Hereditary Breast & Ovarian Cancer ... takes us through the lives of women - and men - who are dealing ...
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University ... the Life Sciences Initiative aimed at enhancing Purdue’s life sciences research and graduate ... True” capital campaign. , The investment will result in cohesive efforts across several ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... enterprise focused on cancer patients, today announced a new partnership with the ... battling this rare type of non-Hodgkin’s lymphoma, their families and physicians. , ...
(Date:10/13/2015)... Diego, CA (PRWEB) , ... October 13, 2015 ... ... launch of its newest technology platform, ENGAGE, at HIMSS’s Patient Engagement Summit ... to end. , ENGAGE delivers innovative health programs and interventions via mobile devices ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)...  Graduate students across the country, with an ... soon have the opportunity to learn about a ... discovery and development process. Eli Lilly and Company ... leaders from academic institutions to create an elective ... Drug Development."  Lilly will formally unveil the eLearning ...
(Date:10/13/2015)... SAN FRANCISCO , October 13, 2015 ... expected to reach USD 26.8 billion by 2022, according ... Anesthesia and respiratory devices, owing to their capability to ... expected to witness a substantial growth. --> ... reach USD 26.8 billion by 2022, according to a ...
(Date:10/13/2015)... , Oct. 13, 2015   Micell Technologies ... DESSOLVE I and II trials of its MiStent Sirolimus ... ® ) were presented at the 27th Annual ... San Francisco , October 11-15. TCT ... cardiovascular medicine. MiStent SES was designed to optimize vessel ...
Breaking Medicine Technology: